Plasma Rich in Growth Factors in Corneal Endothelial Transplantation

Recruiting now · Not applicable

Conditions studied: Fuchs' Endothelial Dystrophy, Corneal Edema

In brief

The purpose of the study is to determine the safety and efficacy of brief intraoperative corneal endothelial graft incubation in plasma rich in growth factors (PRGF) for reducing postoperative endothelial cell loss.

Key facts

Study ID

NCT06261346

Run by

University of Miami

People needed

100

Starts

2024-07-15

Expected to finish

2027-12-31

Last updated by the study team

2026-04-09

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• undergoing endothelial keratoplasty (DSEK or DMEK) at the Bascom Palmer Eye Institute or Price Vision Group, using corneal graft tissue within 14 days of preservation

You may not qualify if…

• History of corneal transplantation in the study eye, Best corrected visual acuity (BCVA) worse than 20/40 in the contralateral eye, systemic immunosuppression, previous intraocular surgical procedures (other than cataract surgery) such as glaucoma tubes or silicone oil.
• The following special populations will be excluded.
• Adults unable to consent
• Pregnant women
• Prisoners

Where it is running

• Bascom Palmer Eye Institute — Miami, Florida, United States (enrolling)
• Price Vision Group — Indianapolis, Indiana, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.